Analyst Reco. RxSight, Inc.

Equities

RXST

US78349D1072

Market Closed - Nasdaq Other stock markets 04:00:03 2024-04-18 pm EDT			5-day change	1st Jan Change
51.76 ^USD	-2.03%		-6.42%	+28.37%

Apr. 04	RxSight Launches New Light Adjustable Lens Product	MT
Apr. 04	RxSight, Inc. Announces Commercial Launch of its Newest Light Adjustable Lens??, the LAL+??, and Features Multiple Doctor Presentations at the Upcoming ASCRS Annual Meeting	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Rxsight Insider Sold Shares Worth $997,946, According to a Recent SEC Filing	Apr. 02	MT
Needham Raises Price Target on RxSight to $64 From $53, Maintains Buy Rating	Feb. 29	MT
Oppenheimer Adjusts RxSight Price Target to $61 From $54, Maintains Outperform Rating	Feb. 29	MT
Stifel Adjusts Price Target on RxSight to $54 From $45, Maintains Buy Rating	Feb. 12	MT
Oppenheimer Raises RxSight Price Target to $54 From $50, Maintains Outperform Rating	Jan. 29	MT
Oppenheimer Raises RxSight Price Target to $50 From $46, Maintains Outperform Rating	Jan. 16	MT
Oppenheimer Ups Price Target on RxSight to $46 From $38, Maintains Outperform Rating	Jan. 08	MT
Needham Adjusts Price Target on RxSight to $41 From $35, Keeps Buy Rating	Jan. 08	MT
Wells Fargo Upgrades RxSight to Overweight From Equalweight, Price Target is $42	Dec. 13	MT
Stifel Starts RxSight With Buy Rating, $40 Price Target	Dec. 12	MT
Needham Adjusts RxSight Price Target to $30 From $36, Maintains Buy Rating	Nov. 10	MT
Oppenheimer Adjusts RxSight Price Target to $34 From $29, Maintains Outperform Rating	23-08-08	MT
Needham Adjusts Price Target on RxSight to $34 From $27, Maintains Buy Rating	23-07-12	MT
BTIG Adjusts Price Target on RxSight to $29 From $25, Maintains Buy Rating	23-06-05	MT
Wells Fargo Adjusts Price Target on RxSight to $27 From $17, Maintains Equalweight Rating	23-06-05	MT
Wells Fargo Adjusts RxSight Price Target to $17 From $15, Maintains Equal Weight Rating	23-05-10	MT
Oppenheimer Starts RxSight at Outperform With $23 Price Target, Sees Path to 'Meaningful' Gross Margin Expansion	23-04-13	MT
JPMorgan Adjusts Price Target on RxSight to $20 From $22, Maintains Overweight Rating	23-03-07	MT
Wells Fargo Downgrades RxSight to Equalweight From Overweight, Adjusts Price Target to $14 From $20	22-12-12	MT
Needham Raises RxSight's Price Target to $22 From $19, Maintains Buy Rating	22-08-09	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. RxSight, Inc.

Equities

RXST

US78349D1072

Analyst Reco.

Filters